{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"OS is defined as the time from the date of first dose administration to the date of death.","groups":[{"description":"Participants were planned to receive TAK-500 at recommended doses based on dose escalation cohorts. No participants were enrolled in the expansion phase due to early termination of the study before initiating this phase.","id":"OG000","title":"Dose Expansion: TAK-500"}],"populationDescription":"Due to early study termination, Dose Expansion Phase was not initiated and hence, no data was collected for this outcome measure.","reportingStatus":"POSTED","timeFrame":"Up to approximately 32.8 months","title":"Dose Expansion: Overall Survival (OS)","type":"SECONDARY"}